inflammatory bowel disease, psoriasis, and pulmonary inflammation. 12 Because inflammatory pathways play a crucial role in the pathogenesis of atherosclerosis, 14 these findings support the hypothesis that ADAM17 might be involved in this common disease. Interestingly, our earlier study had revealed that a mouse allele that led to higher Adam17 expression was associated with reduced susceptibility to atherosclerosis, indicating an unexpected antiatherogenic role of ADAM17. 3 Studies of ADAM17 in mice have been hampered by the fact that Adam17-knockout mice (Adam17 ΔZn/ΔZn ) are not viable. These animals die within several hours after birth and show severe epithelial abnormalities. 15 Only recently, hypomorphic Adam17 mice (Adam17 ex/ex ) have been generated, which are partially deficient for Adam17 and have barely detectable levels of Adam17 in all tissues. 16 Until now, conditional knockout mice with Adam17 deletions in myeloid cells, 17 thymic epithelial cells, 18 osteochondroprogenitor cells, 19 leucocytes, 20 and endothelial cells 21, 22 were used to study inflammation (rheumatoid arthritis) and cancer. A mouse model overexpressing Adam17 showed no enhanced shedding activity in vivo despite higher Adam17 mRNA and protein expression. 23 To date, none of these mouse models have been used to study the effect of ADAM17 on atherosclerosis.
Here, we investigate the role of ADAM17 in atherosclerosis after crossing Adam17 ex/ex hypomorphic mice on the atherosclerosis-prone C57BL/6 Ldlr −/− background (C57BL/6.Ldlr
−/−
). Our study reveals that Adam17 ex/ex hypomorphic mice develop significantly larger atherosclerotic lesions at the aortic root compared with control mice. By systematic genome-wide gene expression analyses and functional studies, we unravel a potential molecular mechanism of how ADAM17 protects against atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Atherosclerosis Is Increased in Adam17-Deficient Mice
To investigate the role of Adam17 deficiency in atherosclerosis, hypomorphic Adam17 mice (Adam17 ex/ex ) 16 were crossed onto the atherosclerosis- .Ldlr −/− mice in (B) and (C). *P<0.05; ***P<0.001.
previously described. 16 We also characterized these mice by measuring the animals' weights and a set of clinical chemistry parameters (Tables I and II in the online-only Data Supplement) .
To induce atherosclerosis, male and female Adam17 ex/ex . Ldlr −/− mice were fed a semisynthetic diet for 16 weeks, resulting in a moderate degree of hypercholesterolemia, which is more physiological than feeding on a high-fat, high-cholesterol diet (Tables I and II in the online-only Data  Supplement) . 24 Under these conditions, atherosclerotic plaque size at the aortic root was increased ≈1. 5 (Figure 2A through 2C) . For soluble TNFα, we observed a trend toward decreased plasma levels in male and female mice, which did not reach significance ( Figure 2D ). The release of other ADAM17 substrates was not significantly altered or inconsistent ( Figure III in the online-only Data Supplement). We also tested plasma levels of a set of ADAM17-independent inflammatory mediators (IFNγ, IL-1β, IL-6, IL-10, MCP-1, MIP-1α, MIP-1β, and RANTES) but observed no consistent trend, indicating that Adam17 deficiency did not alter inflammatory signaling per se in our atherosclerosis model ( Figure .Ldlr −/− mice and quantified ADAM17 substrates in the supernatants with and without stimulation with PMA (phorbol 12-myristate 13-acetate), which is an activator of ADAM17 ( Figure 2E through 2H .Ldlr −/− macrophages compared with control macrophages ( Figure 3C ). In these cells, the mRNA abundances of Tnfr1, Tnfr2, and Tnfα were not different in Adam17 mutants compared with wild-type controls ( Figure 3D ), indicating that the observed increases in TNFR2 and TNFα protein were post-transcriptional effects and potentially caused by the lack of ADAM17-mediated shedding from the cell surface.
mTNFα is known to preferentially activate the TNFR2-signaling pathway. 25 To investigate whether elevated amounts of mTNFα and mTNFR2, thus, resulted in an activation of TNFR2 signaling in Adam17-depleted cells, we quantified the phosphorylated form of bone marrow tyrosine kinase in chromosome X (pBMX), which is a downstream marker of TNFR2 but not of TNFR1 activation. This TNFR2-signaling pathway has been shown to positively stimulate cell survival, proliferation, and adhesion, [26] [27] [28] which is opposite to classical TNFR1 signaling that induces antiproliferative effects. We observed an increase of absolute and also of phosphorylated BMX protein in macrophages of Adam17
.Ldlr −/− mice, indicating an activation of TNFR2 signaling in these cells ( Figure 3E and 3F).
To test whether activation of TNFR2 signaling was relevant for gene expression changes in Adam17 mutants, we performed transcriptome-wide expression profiling using microarrays in primary BMDMs of Adam17 ) and no significant activation in aortas. Together, these data indicated a stronger induction of TNFR2 by membrane-bound TNFα than of TNFR1 signaling in Adam17-deficient cells.
Adam17 Deficiency Promotes Proatherogenic Cell Functions
Apoptosis, proliferation, and adhesion are central cellular functions in atherogenesis and are controlled through both TNFR-signaling pathways, such that TNFR1 is associated with apoptosis induction and antiproliferative functions, whereas TNFR2 inhibits apoptosis and promotes proliferative functions. 29 .Ldlr −/− mice after incubation with staurosporine and cycloheximide ( Figure 4A ). We also found that .Ldlr −/− mice adhered stronger to matrigel-coated wells than macrophages of control mice ( Figure 4D ) and displayed higher expression levels of the ICAM1 ( Figure 4E ), which is another substrate of ADAM17.
To validate our findings in an independent model, we knocked down Adam17 in RAW264.7 macrophages using siRNA (small interfering RNA; Figure VA in the online-only Data Supplement). Consistently, we found that Adam17 knockdown reduced apoptosis ( Figure 5A ) and increased proliferation ( Figure 5B and 5C). With respect to adhesion, we showed that Adam17 knockdown in RAW264.7 increased adhesion to matrigel-coated wells ( Figure 5D ), but even more physiologically relevant, primary BMDMs treated with Adam17 siRNA showed stronger adhesion to primary vascular endothelial cells from C57BL/6 mice ( Figure 5E ). Notably, RNAi (RNA interference)-mediated knockdown of Adam17 in these endothelial cells further increased adhesion of macrophages, and strongest adhesion was observed when both cell types were treated with siRNA against Adam17 ( Figure 5E ). Because immunofluorescent staining had also revealed ADAM17 expression in VSMCs ( Figure ID in the online-only Data Supplement), we next depleted Adam17 in the vascular aortic smooth muscle cell line (MOVAS) using siRNA ( Figure VB in the online-only Data Supplement). Here, the knockdown of Adam17 resulted in a reduction of apoptosis and a slight increase in proliferation rates ( Figure 5F though 5H). Together, RNAi studies of Adam17 in 3 atherosclerosisrelevant cells types, which we had shown to express ADAM17 in atherosclerotic lesions in vivo ( Figure I in the online-only Data Supplement), revealed proatherogenic cellular phenotypes on depletion of ADAM17, where effects on adhesion and apoptosis were strongest in all investigated cell types.
Tnfr2 Knockdown in Adam17-Depleted Cells Restores Cell Functions
Because we had found that TNFR2 signaling was overactivated in the absence of Adam17, we next wanted to investigate whether changes of cell functions caused by Adam17 depletion were dependent on TNFR2. Thus, we performed double-knockdown experiments in RAW264.7 macrophages and MOVAS and investigated whether siRNA-mediated codepletion of both Tnfr2 and Adam17 would restore cell functions back to normal (Figures VI and VII in the onlineonly Data Supplement). As shown in Figure 6A through 6D, Adam17 deficiency increased proliferation in both cell types, and knockdown of Tnfr2 in Adam17-depleted cells attenuated these effects. Consistently, Tnfr2 depletion also restored the levels of apoptosis in Adam17-depleted macrophages ( Figure  6E ) and also in VSMCs ( Figure 6F ). Thus, these data support that the proatherogenic cell-specific effects in Adam17-depleted cells may depend on TNFR2 signaling. 
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The upstream regulator analysis was performed using the Ingenuity Pathways Analysis (www.ingenuity.com). The top 3 pathways are shown. Levels of significance and activation Z-scores were calculated according to standard procedures of the software. IFN indicates interferon; IL, interleukin; and TNF, tumor necrosis factor. Figure 7 ; Figure  VIII in the online-only Data Supplement). Significantly less apoptotic cells were detected in lesions of Adam17-deficient mice in relation to total cell numbers ( Figure 7C ) and plaque area ( Figure 7D ), corroborating results from in vitro studies ( Figures 4A, 5A , and 5F).
We Figure 8A and 8B). Here, we detected significantly more Mac2-positive macrophages ( Figure 8C ) Figure 5 . Adam17 (a disintegrin and metalloproteinase 17) deficiency affects apoptosis, proliferation, and adhesion in mouse RAW264.7 macrophages and in mouse vascular smooth muscle cells. A, Apoptosis assay in RAW264.7 macrophages after siRNA (small interfering RNA) knockdown of Adam17 (n=4) or after using a scrambled (SCR) siRNA oligonucleotide control (n=4). Apoptosis in RAW264.7 macrophages was stimulated with staurosporine (0.25 μmol/L) or cycloheximide (10 ng/mL). Caspase activity is given as luminescence intensity (LI). B, Cell proliferation in RAW264.7 macrophages after Adam17 siRNA-mediated knockdown (n=4) or in SCR RNAi (RNA interference) control (n=4). C, Cell proliferation in RAW264.7 macrophages after Adam17 siRNA-mediated knockdown (n=4) or in SCR RNAi control (n=4) at time point 96 h as indicated in (B). D, Adhesion of RAW264.7 macrophages after siRNA-mediated knockdown of Adam17 (n=4) or in SCR RNAi control (n=4) and with or without stimulation with PMA (100 pmol/mL). E, Adhesion of wild-type primary bone marrowderived macrophages (BMDMS) to a wild-type mouse primary vascular endothelial cell line (EC). Either BMDMs or vascular ECs or both cell types were treated with siRNAs against Adam17 or with SCR siRNA control oligonucleotides as indicated in the legend. Experiments were performed in quadruplicates. F, Apoptosis assay in a vascular smooth muscle cell line (MOVAS) after siRNA knockdown of Adam17 (n=4) and after using scrambled (SCR) siRNA control oligonucleotides (n=4). Apoptosis in MOVAS cells was stimulated with staurosporine (0.25 μmol/L) or cycloheximide (10 ng/mL). Caspase activity is given as LI. G, Cell proliferation in MOVAS cells after Adam17 siRNA-mediated knockdown (n=4) and in SCR RNAi control (n=4). H, Cell proliferation in MOVAS cells after Adam17 siRNA-mediated knockdown (n=4) or in SCR RNAi control (n=4) at time point 96 h as indicated in (G).*P<0.05; **P<0.01; ***P<0.001. .Ldlr −/− mice ( Figure 8G and 8H) . These data are confirmatory of our in vitro results, revealing that the in vivo effects on proliferation were rather subtle ( Figures 4B, 4C , 5B, 5C, 5G, and 5H) and suggesting that the higher abundance of macrophages in plaques from Adam17-deficient mice ( Figure 8C ) might be rather a consequence of resistance to apoptosis ( Figures 4A  and 5A ) and increased adhesion ( Figures 4D, 4E, 5D , and 5E).
In summary, the histological cellular analysis validated our in vitro studies of the mechanisms of Adam17 deficiency, Figure 6 . Knockdown of Tnfr2 in Adam17-depleted cells restore wild-type cell functions. A, Cell proliferation assay in RAW264.7 macrophage cell line after siRNA (small interfering RNA)-mediated knockdown of Adam17 (n=4), Tnfr2 (n=4), double knockdown of Adam17/Tnfr2 (n=4) or using scrambled (SCR) RNAi (RNA interference) control oligonucleotides (n=4). For comparison, P values of all proliferation data are given in Table VII in the online-only Data Supplement. B, Cell proliferation assay in RAW264.7 macrophages after siRNA knockdown of Adam17 (n=4), Tnfr2 (n=4), double knockdown of Adam17/Tnfr2 (n=4) or using scrambled (SCR) RNAi controls (n=4) at time point 96 h as indicated in (A). C, Cell proliferation assay in vascular smooth muscle cell line (MOVAS) after siRNA knockdown of Adam17 (n=4), Tnfr2 (n=4), double knockdown of Adam17/Tnfr2 (n=4) or after using scrambled (SCR) RNAi controls (n=4). For comparison, all P values of all proliferation data are given in Table VII in the online-only Data Supplement. D, Cell proliferation assay in vascular smooth muscle MOVAS cells after siRNA knockdown of Adam17 (n=4), Tnfr2 (n=4), double knockdown of Adam17/Tnfr2 (n=4) or using scrambled (SCR) RNAi controls (n=4) at time point 96 h as indicated in (C). E, Apoptosis assay in RAW264.7 macrophages after siRNA knockdown of Adam17 (n=4), Tnfr2 (n=4), double knockdown of Adam17/Tnfr2 (n=4) or using scrambled (SCR) RNAi controls (n=4). For comparison, P values of all proliferation data are given in Table VIII in the online-only Data Supplement. F, Apoptosis assay in vascular smooth muscle MOVAS cells after siRNA knockdown of Adam17 (n=4), Tnfr2 (n=4), double knockdown of Adam17/Tnfr2 (n=4) or using scrambled (SCR) RNAi controls (n=4). *P<0.05. thereby establishing ADAM17 as a modulator of atherosclerosis in vivo.
Discussion
Using a hypomorphic Adam17-deficient mouse model on the Ldlr −/− background, we established the metalloproteinase ADAM17 as a protective factor of atherosclerosis. At the molecular level, Adam17 deficiency led to a reduced shedding of membrane-bound mTNFR2 and mTNFα. This enhanced the abundance of mTNFR2 and mTNFα at the cell surface, coinciding with increased TNFR2 pathway signaling. As a consequence, apoptosis levels were decreased and proliferation rates increased in macrophages and VSMCs. Because knocking down Tnfr2 in Adam17-deficient macrophages or SMCs restored levels of apoptosis and cell proliferation back to wild-type levels, we conclude that the control of TNFR2 signaling is an important effector pathway for ADAM17 in protecting from atherosclerosis.
Because of its well-established molecular function in releasing proinflammatory soluble TNFα, 9,15 a protective role of ADAM17 in atherosclerosis might at first seem counterintuitive. However, ADAM17 is also involved in potentially atheroprotective cell functions such as shedding of both TNFα receptors and cell adhesion molecules. [31] [32] [33] Given this overall promiscuous nature, it was not obvious before our present study whether the depletion of Adam17 would push the balance toward a pro-or an antiatherogenic net effect. Our current study corroborates and extends our previous work where we have identified Adam17 as a candidate gene of atheroprotection using expression quantitative trait locus mapping in mice. 3 Here, we provide mechanistic insight into how ADAM17 executes this role. Although several mouse models with tissue-specific Adam17 deficiency have been established before, [17] [18] [19] 21, 22 our study is the first to offer causal evidence for any role of ADAM17 in modulating atherosclerosis. Previous work by Canault et al 4 has already established the presence of ADAM17 in atherosclerotic lesions of humans and ApoE −/− mice, where macrophages likely contributed to ADAM17 expression. These authors also suggested that atherosclerotic lesions expressing ADAM17 may contribute to elevated levels of circulating TNFα in ApoE −/− mice on a high-fat diet. 4 Given the fact that Adam17 is highly expressed in macrophages ( Figure 1A ; Figures I and II in the online-only Data Supplement) and because macrophages are present in atherosclerotic lesions, this is not unexpected and indeed consistent with results from the current study. Beyond correlative evidence, the study by Caunault et al, however, did not investigate a causal role of Adam17 in atherosclerosis, for example, by loss-of-function experiments. How does our description of an antiatherogenic function of ADAM17 relate to the literature on the role of TNFα signaling in atherosclerosis? Overall, apart from the onset of atherosclerotic lesions, where TNFα is thought to delay lesion formation via impairing cholesterol accumulation in macrophages, 34 the net effect of TNFα signaling seems to promote disease. [35] [36] [37] [38] [39] This conclusion bases on the studies of atherosclerotic lesions sizes in TNFα-knockout mice and the observation of decreased vascular endothelial cell adhesiveness and decreased inflammatory factor expression in atherosclerotic plaques. In these earlier studies, [35] [36] [37] [38] [39] proatherogenic effects of TNFα were, however, related mostly to the fact that soluble TNFα promotes classical inflammatory TNFR1 signaling.
In our present work, we extend these earlier reports by focusing on the membrane-resident mTNFα and TNFR2, which were particularly increased in the absence of ADAM17, likely because of reduced shedding. Previous work had further suggested that mTNFα stabilized membrane protein expression of TNFR2, 40 thus potentially explaining why the levels of membrane TNFR2 but not TNFR1 were higher in the Adam17 mutants. Because it is TNFR2 signaling and not TNFR1 signaling, that is preferentially activated by mTNFα, 25 an overactivation of TNFR2 signaling through both higher mTNFα and mTNFR2 protein (Figure 3 ) might, thus, promote atherosclerosis. Consistently, a study by Chandrasekharan et al 41 has shown that Tnfr2-deficient mice develop less atherosclerosis on the ApoE −/− background. Together, the activation of TNFR2 signaling seems to be a plausible effector mechanism promoting atherosclerosis in the Adam17 knockout.
TNFR2 signaling has previously been associated with an antiapoptotic and proliferative cellular response 30 and with increased adhesion via the induction of ICAM1 expression in different mouse models. 42, 43 It is these antiapoptotic, proliferative, and proadhesive responses that we also see in our in vitro and in vivo analysis of the Adam17 mutant: the direction of effects is identical in the Adam17 ex/ex knockout macrophages (Figure 4) , the Adam17 siRNA-treated macrophages, VSMCs, and endothelial cells ( Figure 5) . Notably, all cell functions that we investigated were restored to normal when depleting Tnfr2 in Adam17-deficient cells, further supporting an important role of this receptor when Adam17 is depleted. On the contrary, the observed effects in our in vitro and in vivo experiments contrasted the functions classically associated with TNFR1 signaling, such as TNFR1-dependent induction of inflammation and apoptosis and reduction of proliferation, [44] [45] [46] thus further speaking against TNFR1 as a major effector in our Adam17 hypomorphic mouse model.
In this context, the function of ADAM17 in the vasculature is likely pleiotropic and cell context dependent and its effect on TNF signaling is only one of multiple facettes of the protease: ADAM17 enzyme activity and substrate specificity are selective and regulated. Similarly complex, the role of proliferation and apoptosis in atherosclerosis is multifacetted, and inhibition of cellular proliferation and induction of apoptosis, such as ascribed here to ADAM17 function, is not necessarily atheroprotective under all circumstances. For instance, apoptosis in macrophages might indeed attenuate early lesion progression but can at later stages also induce secondary inflammation and plaque rupture, 47 and apoptosis in vascular endothelial cells may be proatherogenic. 48 Summarizing, the cell type-specific ADAM17 functions will have to be integrated to understand how the net atheroprotective output is achieved. It is likely that also other ADAM17 substrates will modulate atherosclerosis, including adhesion factors that are directly or indirectly shed by ADAM17. We do not claim that control of TNFR2 activity in macrophages and VSMCs is the single effector mechanism for ADAM17's role in protection from atherosclerosis. We also do not claim that TNFR1 has no function at all for Adam17's role in atherosclerosis. Reasons to be cautious are data from existing knockouts of other ADAM17 substrates, such as ICAM1, 49 VCAM1, 50 CX3CL1 (fractalkine), 51 or IL-1 52 depletion, which show decreased atherosclerosis. Although we did not see consistent changes in the shedding of these substrates, we do note that not all known substrates of ADAM17 have been tested in our study. Thus, it is possible that overall small but co-ordinated changes in a variety of ADAM17 substrates, other than TNFR2, may add up to an atheroprotective function.
Over the past years, ADAM17 has become a therapeutic target in several cancers and inflammatory diseases. [53] [54] [55] [56] [57] [58] [59] Here, therapeutic approaches aim to inhibit ADAM17 activity, and several agents are already used in different preclinical models and clinical trials. 60 Results of the current study now show that a general inhibition of ADAM17 may lead to an upregulation of atherosclerosis-associated cell functions by promoting TNFR2 signaling. Similarly, agonists of TNFR2 are considered for depleting insulin-specific autoreactive T cells in type 1 diabetes mellitus treatment, [60] [61] [62] and our results suggest that an increased atherosclerosis risk might need to be considered as a side effect as well. Although a recent meta-analysis has shown that TNFα inhibition leads to a significant reduction of hard cardiovascular end points (relative risk 0.7; P=0.005) in patients with rheumatoid arthritis, 63 the exact mechanisms of ADAM17 in the vascular wall of humans and in the pathogenesis of human atherosclerosis remains to be determined.
Taken together, results of the current study establish ADAM17 as a protective factor of atherosclerosis in mice and show that a constitutive upregulation of TNFR2 signaling in Adam17 deficiency promotes proatherogenic cellular functions in vitro and in vivo.
